PharmaCyte Biotech, Inc. (PMCB) Income Statement
PMCB FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsPMCB revenue and net income
PMCB growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | −163.4% | — | — | — |
| EPS (diluted) | −199.6% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PMCB quarterly EPS vs estimates
PharmaCyte Biotech beat the analyst EPS estimate in 1 of the last 4 quarters.
PMCB income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 |
| Research & development | $391,301 | $438,416 | $407,431 | $468,536 | $690,937 | $916,249 | $301,221 | $460,052 | $2.0M | $1.2M |
| Sales, general & admin | $4.9M | $3.9M | $7.4M | $6.0M | $3.7M | $1.8M | $3.5M | $3.6M | $5.0M | $3.3M |
| Total operating expenses | $6.9M | $4.4M | $8.5M | $6.5M | $4.4M | $3.6M | $3.8M | $4.1M | $7.0M | $4.4M |
| Operating income | −$6.9M | −$4.4M | −$8.5M | −$6.5M | −$4.4M | −$3.6M | −$3.8M | −$4.1M | −$7.0M | −$4.4M |
| Interest income | $733,351 | $1.4M | $3.4M | $1.9M | $157,645 | $0 | — | — | — | — |
| Interest expense | — | — | — | $0 | $509 | $3,046 | $453 | $0 | $0 | $1,539 |
| Income before taxes | −$19.4M | $30.7M | $333,763 | −$4.3M | −$4.2M | −$3.6M | −$3.8M | −$4.1M | −$6.8M | −$4.4M |
| Income taxes | — | — | −$6.5M | −$1.9M | −$153,000 | $3,046 | $453 | −$33,401 | −$152,588 | −$4,442 |
| Net income | −$19.4M | $30.7M | $333,763 | −$4.3M | −$4.2M | −$3.6M | −$3.8M | −$4.1M | −$6.8M | −$4.4M |
| EBITDA | −$5.3M | −$4.4M | −$6.5M | −$6.5M | −$4.2M | −$3.5M | −$3.8M | −$4.1M | −$6.8M | −$4.4M |
| EPS (diluted) | −$2.65 | $2.66 | −$0.92 | −$0.21 | −$0.80 | −$2.36 | −$3.67 | −$5.23 | −$9.60 | −$15.45 |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $60,000 | $61,946 | $93,113 | $141,085 | $95,157 | $126,734 | $118,196 | $97,470 | $96,016 | $94,183 | $126,732 | $82,033 |
| Sales, general & admin | $946,708 | $899,882 | $2.0M | $1.2M | $753,148 | $1.8M | $842,056 | $1.0M | $1.2M | $839,553 | $1.7M | $1.3M |
| Total operating expenses | $1.0M | $2.5M | $2.1M | $1.4M | $848,305 | $1.0M | $960,252 | $1.1M | $1.3M | $1.2M | $1.9M | $1.4M |
| Operating income | −$1.0M | −$2.5M | −$2.1M | −$1.4M | −$848,305 | −$1.0M | −$960,252 | −$1.1M | −$1.3M | −$1.2M | −$1.9M | −$1.4M |
| Interest income | $166,278 | $78,503 | $230,668 | $206,387 | $217,793 | $229,875 | $255,692 | $382,562 | $547,432 | $747,098 | $881,662 | $894,181 |
| Income before taxes | −$5.1M | −$4.4M | $746,860 | −$7.4M | −$8.4M | $11.7M | −$3.0M | −$1.5M | $23.4M | $1.3M | −$619,537 | $2.8M |
| Income taxes | — | — | — | — | — | — | — | — | $1.8M | — | −$1,868 | −$894,000 |
| Net income | −$5.1M | −$4.4M | $746,860 | −$7.4M | −$8.4M | $11.7M | −$3.0M | −$1.5M | $23.4M | $1.3M | −$619,537 | $2.8M |
| EBITDA | −$1.0M | −$961,828 | −$2.1M | −$1.4M | −$848,305 | — | −$960,252 | −$1.1M | −$1.3M | — | −$1.9M | −$1.4M |
| EPS (diluted) | −$0.54 | −$0.01 | −$0.17 | −$1.24 | −$1.23 | $1.58 | −$0.44 | −$0.39 | $1.90 | −$0.32 | −$0.07 | −$0.26 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PMCB's financial statements (latest annual report filed July 29, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PMCB financial results
PharmaCyte Biotech reported no revenue in fiscal year 2026 (ended April 30, 2026). It had a net loss of $19.4 million. Diluted earnings per share came to −$2.65.
See the PMCB stock overview for the latest quote and news, or the PMCB chart for price history and technical indicators.
PMCB income statement FAQ
Does PharmaCyte Biotech have revenue?
PharmaCyte Biotech reported no revenue for fiscal year 2026, which ended on April 30, 2026.
Is PharmaCyte Biotech profitable?
No. PharmaCyte Biotech reported a net loss of $19.4 million in fiscal 2026.
How much does PharmaCyte Biotech spend on research and development?
PharmaCyte Biotech spent $0.4 million on research and development in fiscal 2026.
What are PharmaCyte Biotech's earnings per share?
PharmaCyte Biotech earned $-2.65 per diluted share in fiscal 2026, compared with $2.66 a year earlier.
When does PharmaCyte Biotech's fiscal year end?
PharmaCyte Biotech's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on July 29, 2026.